As of October 27, 2026, Retension Pharmaceuticals, Inc. is a publicly traded company (Nasdaq: RTSN). The largest holder reporting an active stake on Schedule 13D is Eric Keller, the executive officer and a director, at 7.07%. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13D, October 14, 2026).
About to sign with, pay or invest in Retension Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Retension Pharmaceuticals, Inc. a real, registered company?
- Retension Pharmaceuticals, Inc. files with the SEC under CIK 2002988 (its SEC filings).
- Its shares are listed under the ticker RTSN on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Mclean, Virginia, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Retension Pharmaceuticals, Inc. in our court records and SEC 8-K records (as of 2026-10-27).
- Leadership changes: the latest reported is Robert Wong, Chief Accounting Officer (Form 8-K filed 2026-10-23). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names The B Group, Inc. (filed 2026-10-16).
Who are Retension Pharmaceuticals, Inc.'s owners and officers?
Retension Pharmaceuticals, Inc.: incorporated in Delaware; business address in Mclean, Virginia; industry Pharmaceutical Preparations (Form D, 2026-10-23).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2025-05-06)
- : Director (Form D, 2025-05-06)
- : Director (Form D, 2025-05-06)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-16 | The B Group, Inc. | 10% |
| Schedule 13G, 2026-10-16 | Pvg Asset Management Corp | 8.3% |
| Schedule 13G, 2026-10-15 | Laurence W. Lytton | 7.4% |
| Schedule 13D, 2026-10-14 | Eric Keller | 7.07% |
Want the whole picture on Retension Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Retension Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Retension Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-10-23 | Robert Wong | Chief Accounting Officer | appointed | 2026-11-02 |
Which insiders own Retension Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- B Group, Inc., a 10% owner: 833,333 shares, held indirectly through a see note 1 (Form 3, 2026-10-16).
- , the chief executive and a director: 464,407 shares (Form 4, 2026-10-13).
- , the chief scientific officer: 409,243 shares, 406,603 held directly and 2,640 indirectly (Form 4, 2026-10-13).
- , a director: 22,517 shares, 12,517 held directly and 10,000 indirectly (Form 4, 2026-10-13).
- , a director: 6,666 shares (Form 4, 2026-10-13).
Shares only: the company's cover page does not give one share count for a single class, so no percentage is worked out.
How much has Retension Pharmaceuticals, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-05-06 | $12.29M | $20M |
| Form D, 2023-12-05 | $5.82M | $8M |
Latest IPO step: Retension Pharmaceuticals, Inc. filed its final IPO prospectus, ticker RTSN (424B4, 2026-10-09).
IPO filings: 424B4, 2026-10-09, S-1/A, 2026-10-07, S-1/A, 2026-10-05, S-1, 2026-09-18; ticker RTSN on Nasdaq Capital Market.
Keep reading
More on Retension Pharmaceuticals, Inc. and the records around it.
Retension Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- IPO filing Oct 2026
Companies that share a holder
- The B Group, Inc. also filed stake reports on 1 other company: NRx Pharmaceuticals, Inc. (Aug 2025)
- Laurence W. Lytton also filed stake reports on 28 other companies: Rank One Computing Corp (Aug 2026), MDxHealth SA (Aug 2026), AYTU BIOPHARMA, INC (Aug 2026)
Related pages
Leadership changes5%+ holdersIPO filings
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/retension-pharmaceuticals